[Skip navigation] FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Achives
Office of Surveillance and Epidemiology (OSE)
(formerly Office of Drug Safety)
Regulations, Guidances, and Manual of Policies and Procedures (MaPPs)

Federal Regulations

  • The Federal Food, Drug, and Cosmetic Act,  Chapter V, Drugs and Devices.  The Federal Food, Drug, and Cosmetic Act (the Act), was signed into law in 1938 and has been amended several times since; enforcement accounts for about 90 percent of FDA's workload. This statue and its amendments provide for the regulation of foods, human and animal drugs, medicated animal feeds, medical devices, and cosmetics.

  • 21 Code of Federal Regulations
    •  21 Code of Federal Regulations Section 310.305  This section of the code is titled; "Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications."  It addresses the type of reports that are required to be submitted to the Agency (FDA) when an adverse reaction occurs with a drug that is not required to have an NDA (pre-1938 marketed drugs).
    • 21 Code of Federal Regulations Section 314.80  This section of the code is titled; "Postmarketing reporting of adverse drug experiences."  It addresses the type of reports that are required to be submitted to the Agency (FDA) when an adverse reaction occurs with a drug that is marketed under an approved New Drug Application.
    • 21 Code of Federal Regulations Section 314.90  This section of the code is titled  "Applications for FDA approval to market a new drug: Waivers," and addresses waivers to requirements under Section 314.50 through 314.81.  
    • 21 Code of Federal Regulations Section 314.98 This section of the code is titled, "Postmarketing Reports." It addresses the requirements regarding the reporting and recordkeeping of adverse drug experiences for abbreviated new drug applications.
    • 21 Code of Federal Regulations, Section 201.10(c)  This section of the code is titled "Labeling: Drugs; statement of ingredients," and addresses some reasons the labeling of a drug may be misleading.
    • 21 Code of Federal Regulations Part 208 This part of the code is titled, "Medication Guides for Prescription Drug Products." It addresses the general provisions and general requirements for Medication Guides.

Guidances

Clinical/Medical

Electronic Submissions (draft)

International Conference on Harmonisation, Efficacy

Procedural (Draft)

Manual of Policies and Procedures (MaPPs)

pdf.gif (146 bytes) PDF requires the free Adobe Acrobat Reader.

Updated: March 16, 2006
horizonal rule